BioInvent International AB announced that the China National Intellectual Property Administration (CNIPA) has issued a notice of allowance, informing the company that a patent application relating to the anti-Fc?RllB antibody BI-1206 is granted contingent on payment of the issue fee. This patent allowance is a strategic milestone in BioInvent's exclusive licensing agreement with CASI Pharmaceuticals Inc., a U.S. biopharmaceutical company with an established clinical development and commercial infrastructure in China. In 2020, CASI gained the rights for the development and commercialization of BI-1206 in mainland China, Taiwan, Hong Kong and Macau. Other patents in the same patent family have already been granted by the European Patent Office and in several other countries, including the US and Japan. The company also has related patent applications pending in some countries.